The use of GLP-1 receptor agonists and the DPP-4 inhibitors have clearly demonstrated that targeting the GLP-1 axis has a great therapeutic value for T2D and obesity treatment (13, 136, 137). Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.